S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
NASDAQ:ADMA

ADMA Biologics (ADMA) Stock Price, News & Analysis

$5.52
+0.16 (+2.99%)
(As of 03/1/2024 ET)
Today's Range
$5.32
$5.57
50-Day Range
$4.24
$5.52
52-Week Range
$2.94
$5.72
Volume
3.59 million shs
Average Volume
2.05 million shs
Market Capitalization
$1.25 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.50

ADMA Biologics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.25 Rating Score
Upside/​Downside
35.9% Upside
$7.50 Price Target
Short Interest
Healthy
2.72% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.45mentions of ADMA Biologics in the last 14 days
Based on 35 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
33.33%
From $0.24 to $0.32 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.82 out of 5 stars

Medical Sector

243rd out of 950 stocks

Biological Products, Except Diagnostic Industry

36th out of 153 stocks


ADMA stock logo

About ADMA Biologics Stock (NASDAQ:ADMA)

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

ADMA Stock Price History

ADMA Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Q4 2023 ADMA Biologics Inc Earnings Call
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
ADMA Biologics, Inc.: ADMA Biologics Announces CFO Transition
Forecasting The Future: 4 Analyst Projections For ADMA Biologics
ADMA Biologics' CFO to step down
ADMA Biologics Announces CFO Transition
ADMA Biologics earnings preview: what Wall Street is expecting
Earnings Preview For ADMA Biologics
ADMA Biologics (ADMA) Scheduled to Post Earnings on Wednesday
See More Headlines
Receive ADMA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ADMA Biologics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2023
Today
3/02/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:ADMA
Employees
617
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.50
High Stock Price Target
$10.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+35.9%
Consensus Rating
Buy
Rating Score (0-4)
3.25
Research Coverage
4 Analysts

Profitability

Net Income
$-65,900,000.00
Pretax Margin
-10.94%

Debt

Sales & Book Value

Annual Sales
$258.21 million
Cash Flow
$0.05 per share
Book Value
$0.60 per share

Miscellaneous

Free Float
212,410,000
Market Cap
$1.25 billion
Optionable
Optionable
Beta
0.43
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report














ADMA Stock Analysis - Frequently Asked Questions

Should I buy or sell ADMA Biologics stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ADMA Biologics in the last twelve months. There are currently 3 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ADMA shares.
View ADMA analyst ratings
or view top-rated stocks.

What is ADMA Biologics' stock price target for 2024?

4 equities research analysts have issued 12 month price objectives for ADMA Biologics' shares. Their ADMA share price targets range from $6.00 to $10.00. On average, they anticipate the company's stock price to reach $7.50 in the next twelve months. This suggests a possible upside of 35.9% from the stock's current price.
View analysts price targets for ADMA
or view top-rated stocks among Wall Street analysts.

How have ADMA shares performed in 2024?

ADMA Biologics' stock was trading at $4.52 at the beginning of the year. Since then, ADMA shares have increased by 22.1% and is now trading at $5.52.
View the best growth stocks for 2024 here
.

Are investors shorting ADMA Biologics?

ADMA Biologics saw a drop in short interest in the month of February. As of February 15th, there was short interest totaling 6,150,000 shares, a drop of 10.1% from the January 31st total of 6,840,000 shares. Based on an average trading volume of 2,110,000 shares, the days-to-cover ratio is currently 2.9 days.
View ADMA Biologics' Short Interest
.

When is ADMA Biologics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our ADMA earnings forecast
.

How were ADMA Biologics' earnings last quarter?

ADMA Biologics, Inc. (NASDAQ:ADMA) issued its quarterly earnings results on Wednesday, November, 8th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.01). The biotechnology company earned $67.30 million during the quarter, compared to the consensus estimate of $62.13 million. ADMA Biologics had a negative net margin of 10.94% and a positive trailing twelve-month return on equity of 0.49%. The business's revenue was up 63.7% on a year-over-year basis. During the same period in the prior year, the business earned ($0.08) earnings per share.

What ETF holds ADMA Biologics' stock ?

Virtus LifeSci Biotech Products ETF holds 88,335 shares of ADMA stock, representing 1.90% of its portfolio.

What guidance has ADMA Biologics issued on next quarter's earnings?

ADMA Biologics issued an update on its FY 2025 earnings guidance on Wednesday, February, 28th. The company provided EPS guidance of for the period. The company issued revenue guidance of $380.0 million-.

What is Adam S. Grossman's approval rating as ADMA Biologics' CEO?

9 employees have rated ADMA Biologics Chief Executive Officer Adam S. Grossman on Glassdoor.com. Adam S. Grossman has an approval rating of 29% among the company's employees. This puts Adam S. Grossman in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ADMA Biologics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ADMA Biologics investors own include Matinas BioPharma (MTNB), Pennsylvania Real Estate Investment Trust (PEI), Organigram (OGI), Gran Tierra Energy (GTE), Tilly's (TLYS), Bionano Genomics (BNGO), Novan (NOVN), CNBX Pharmaceuticals (CNBX), Zosano Pharma (ZSAN) and DHT (DHT).

Who are ADMA Biologics' major shareholders?

ADMA Biologics' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (5.71%), Nuveen Asset Management LLC (5.03%), Stonepine Capital Management LLC (4.08%), Perceptive Advisors LLC (2.85%), Assenagon Asset Management S.A. (1.75%) and Dimensional Fund Advisors LP (1.54%). Insiders that own company stock include Adam S Grossman, Brian Lenz, Bryant Fong, Jerrold B Grossman, Perceptive Advisors Llc and Young Kwon.
View institutional ownership trends
.

How do I buy shares of ADMA Biologics?

Shares of ADMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ADMA) was last updated on 3/2/2024 by MarketBeat.com Staff